CN109022569B - 一种用于预测慢性乙肝肝纤维化的miRNA组合物 - Google Patents
一种用于预测慢性乙肝肝纤维化的miRNA组合物 Download PDFInfo
- Publication number
- CN109022569B CN109022569B CN201811052246.8A CN201811052246A CN109022569B CN 109022569 B CN109022569 B CN 109022569B CN 201811052246 A CN201811052246 A CN 201811052246A CN 109022569 B CN109022569 B CN 109022569B
- Authority
- CN
- China
- Prior art keywords
- mirna
- mir
- hsa
- chronic hepatitis
- liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 208000000419 Chronic Hepatitis B Diseases 0.000 title claims abstract description 27
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 27
- 206010019668 Hepatic fibrosis Diseases 0.000 title claims abstract description 24
- 108091070501 miRNA Proteins 0.000 title abstract description 85
- 239000000203 mixture Substances 0.000 title abstract description 30
- 108091044802 Homo sapiens miR-1285-1 stem-loop Proteins 0.000 claims abstract description 13
- 108091068856 Homo sapiens miR-98 stem-loop Proteins 0.000 claims abstract description 13
- 238000013399 early diagnosis Methods 0.000 claims abstract description 4
- 239000002679 microRNA Substances 0.000 abstract description 80
- 210000004185 liver Anatomy 0.000 abstract description 19
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 12
- 239000000090 biomarker Substances 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 5
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 238000005516 engineering process Methods 0.000 abstract description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 238000011529 RT qPCR Methods 0.000 abstract 1
- 238000007689 inspection Methods 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 12
- 238000012163 sequencing technique Methods 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 8
- 208000019423 liver disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 108091032955 Bacterial small RNA Proteins 0.000 description 6
- 101710142246 External core antigen Proteins 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 208000007848 Alcoholism Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108091067995 Homo sapiens miR-192 stem-loop Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 108091030146 MiRBase Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 102000039471 Small Nuclear RNA Human genes 0.000 description 2
- 108020004688 Small Nuclear RNA Proteins 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010223 real-time analysis Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 108091067628 Homo sapiens miR-10a stem-loop Proteins 0.000 description 1
- 108091069013 Homo sapiens miR-206 stem-loop Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091008060 MIR10A Proteins 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 108091028695 MiR-224 Proteins 0.000 description 1
- 108091028684 Mir-145 Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229940124405 anti-hepatitis b virus drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002558 medical inspection Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 108091065212 miR-190b stem-loop Proteins 0.000 description 1
- 108091025686 miR-199a stem-loop Proteins 0.000 description 1
- -1 miR-22l/222 Proteins 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 108091072565 miR-98 stem-loop Proteins 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000011022 operating instruction Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明涉及一种用于预测慢性乙肝肝纤维化的miRNA组合物,所述组合物包括hsa‑miR‑190b,hsa‑miR‑1285‑5p和hsa‑miR‑98‑5p,核苷酸序列分别见SEQ ID NO.1‑3。本发明解决了现有的肝穿刺有创检查以及肝纤维化的无创技术不能完全明确肝纤维化的程度的问题,通过qRT‑PCR对上述miRNA组合物进行检测,可以实现对慢性乙肝肝纤维化的早期诊断,miRNA是细胞的基因调控系统中的重要组成,miRNA作为生物学标志物是一种非侵入性取样,可以在无创条件下通过单独的miRNA或miRNA组合物的表达谱来辅助诊断被试者是否罹患慢性乙肝肝纤维化,提高了诊断的准确率。
Description
技术领域
本发明涉及一种用于预测慢性乙肝肝纤维化的miRNA组合物,属于医学检验技术领域。
背景技术
微小RNA(microRNA)是一类内源性非编码单链小分子RNA,长度为18~24个核苷酸。在人类基因组中已发现超过500个微小RNA编码基因,预测可调控约5300个基因。微小RNA主要与靶mRNA的3’端非翻译区结合,引起靶mRNA沉默(降解或抑制翻译),是一种发挥负调控作用的分子。近年对微小RNA生物功能的研究越来越多,发现其在机体生理及病理方面起重要作用,生理情况下参与细胞的增殖、分化过程,若表达及功能失调则可能导致包括白血病在内的肿瘤的发生,以及病毒、细菌感染等多种病理现象。
微小RNA普遍存在于人类的体液中,性质稳定,可以定量检测,且存在显著的疾病特异性。近年的研究表明,血液、唾液、尿液、乳汁及脑脊液等体液miRNA检测可应用于妊娠等生理状态的判断以及口腔癌、膀胱癌及阿尔海默茨病等疾病的诊断和预后判断。体液特异性miRNA检测的临床意义及应用前景已引起高度关注,miRNA作为一类非编码调节性的小分子RNA有可能取代传统的特异蛋白为代表的生物标志物。体液miRNA含量丰富且性质稳定,具备成为优异生物标志物的潜质,并且拥有以蛋白质为代表的传统生物标志物不具备的特性,无需抗体制备且易于精确定量,可能克服抗原抗体类生物标志物的制备瓶颈。
肝脏是人体内重要的器官之一,肝脏疾病尤其是病毒性肝炎、肝细胞癌、酒精性肝炎等病情重,治疗棘手,严重困扰着人类的健康,研究肝脏疾病的发病机制对其治疗至关重要。不断有研究发现,微小RNA与多种肝脏疾病相关,肝脏中的微小RNA表达异常或缺失可导致肝细胞凋亡、再生,甚至感染等,微小RNA参与众多肝脏疾病的病理发病过程。在众多肝脏疾病中,肝细胞癌和微小RNA的相互关系研究最多。近年研究发现,微小RNA失调和癌症发生发展密切相关,微小RNA参与癌症的病理发病过程。肝细胞癌的发生同样受微小RNA的调控,已发现在肝细胞癌中表达上调的微小RNA有miR-2l、miR-34a、miR-22l/222和miR-224等,而表达下调的有miR-122、miR-145和miR-199a等。
肝纤维化是各种肝脏疾病反复损伤,肝细胞的反复炎症坏死,在肝星状细胞活化等中心事件导致肝脏纤维结缔组织的沉积,是肝脏发展成肝硬化的一个必然过程。Knodell是第一个提出半定量评价肝脏组织学损伤的,以后不断报道了Scheuer,METAVIR,Ishak等肝组织的半定量评分标准,各有其优缺点,我国也开发了自己的GS评分系统。这些评分系统为准确认识肝脏病理损伤的程度起了重要的标准。了解肝脏的肝纤维化的程度有助掌握肝脏的病变程度,以决定是否需要治疗,对于慢性乙肝患者,各种指南均将中度以上肝纤维化定义为抗病毒治疗的条件。但应用这些评分系统就必需进行肝穿刺,肝穿刺的有创性以及本身肝穿刺的局限性,如穿刺组织体积小不能全面反映肝脏病变,以及肝脏病理阅片的主观性等问题限制了肝穿刺病理的推广应用,因此在临床上除了科研,以及属于指南建议的穿刺对象或者有证据显示可能有中度以上的肝纤维化证据,如脾脏肿大,血小板减少等,才会建议患者进行肝组织学检查。所以肝纤维化的无创性诊断长期来得到重视,最早应用于临床的血清学是一些反映细胞外基质代谢的指标如I~IV胶原,透明质酸,层黏蛋白以及基质金属酶等,这些指标曾经广泛应用于临床,但由于其特异性及敏感性均较差,被逐渐淘汰。
因此,寻找到新的诊断方法和更敏感的生物学标志是治疗慢性乙肝肝纤维化迫切需要解决的问题。
发明内容
本发明的目的是解决现有技术的不足,提供一种用于预测慢性乙肝肝纤维化的miRNA组合物。
技术方案
一种用于预测慢性乙肝肝纤维化的miRNA组合物,所述组合物包括hsa-miR-190b,hsa-miR-1285-5p和hsa-miR-98-5p。
进一步,所述hsa-miR-190b的核苷酸序列如SEQ ID NO.1所示。
SEQ ID NO.1:UGAUAUGUUUGAUAUUGGGUUU
进一步,所述hsa-miR-1285-5p的核苷酸序列如SEQ ID NO.2所示。
SEQ ID NO.2:GAUCUCACUUUGUUGCCCAGG
进一步,所述hsa-miR-98-5p的核苷酸序列如SEQ ID NO.3所示。
SEQ ID NO.3:UGAGGUAGUAAGUUGUAUUGUU。
用于检测上述miRNA组合物的引物组,包括针对hsa-miR-190b的特异性引物,针对hsa-miR-1285-5p的特异性引物,针对hsa-miR-98-5p的特异性引物;所述针对hsa-miR-190b的特异性引物包括SEQ ID NO.4所示的正向引物和SEQ ID NO.5所示的反向引物,所述针对hsa-miR-1285-5p的特异性引物包括SEQ ID NO.6所示的正向引物和SEQ ID NO.7所示的反向引物,所述针对hsa-miR-98-5p的特异性引物包括SEQ ID NO.8所示的正向引物和SEQ ID NO.9所示的反向引物。
上述用于检测miRNA组合物的引物组在预测或诊断慢性乙肝肝纤维化方面的应用。采用该引物组,通过qRT-PCR对上述miRNA组合物进行检测,可以实现对慢性乙肝肝纤维化的早期诊断,为慢性乙肝肝纤维化的早期发现和诊断提供参考。
一种慢性乙肝肝纤维化的诊断试剂盒,包括上述用于检测miRNA组合物的引物组。
进一步,所述miRNA组合物的筛选方法包括如下步骤:
(1)样品采集:采集患者新鲜血液,2h内分离,收集血清,并将血清转移至一次性使用无RNA酶的无菌微量离心管中,-80℃保存,备用;
(2)总RNA提取:采用LCS TRK1001试剂盒(LC Sciences)操作说明书进行;
(3)文库构建:使用Illumina Truseq Small RNA Preparation kit试剂盒参照试剂盒说明书Illumina’s TruSeq Small RNA Sample Preparation Guide构建小RNA文库,总RNA链接5'接头和3'接头后经RT-PCR扩增形成小分子RNA的cDNA文库,经过6%TBE变性胶电泳分离,将长度范围在147bp的小分子RNA切胶回收;
(4)第二代测序:cDNA经纯化后在Illumina’s Cluster Station上生成DNA簇后上机(Illumina GAIIx)进行测序,通过Illumina’s Sequencing Control Studio softwareversion 2.8(SCS v2.8)软件实时分析测序图片并使用Illumina's Real-Time Analysisversion 1.8.70(RTA v1.8.70)提取base-calling,提取的原始序列利用ACGT101-miRv4.2(LC Sciences)软件分析,生成RawData数据库,同时去除由于样品制备、测序化学与处理以及测序仪器的光学数码处理而产生的非纯序列,剩下的序列(长度在15和32bases)按照families进行分组,生成mappableReads。Mappable序列与最新版本的miRbase数据库以及测序物种基因组进行序列比对,鉴定该物种已知的miRNA;同时发现新的5p或者3p miRNA序列,鉴定在其它近源物种中已有报道,在该物种中崭新的miRNA序列。其中Mappable序列能与Rfam(ie rRNA,tRNA,snRNA,snoRNA and others),Repbase以及mRNA序列比对上的均被去除。除此之外,为了保证筛选到高质量的基因结果,我们把reads数小于10的基因剔除掉。最后分析实验组和对照组之间差异表达的miRNAs,最终获得hsa-miR-190b,hsa-miR-1285-5p和hsa-miR-98-5p。
本发明的有益效果是:
本发明提供了一种用于预测慢性乙肝肝纤维化的miRNA组合物,通过qRT-PCR对该miRNA组合物进行定量检测,实现对慢性乙肝肝纤维化的早期诊断和预测,解决了现有的肝穿刺有创检查以及肝纤维化的无创技术不能完全明确肝纤维化的程度的问题,miRNA是细胞的基因调控系统中的重要组成,miRNA作为生物学标志物是一种非侵入性取样,可以在无创条件下通过单独的miRNA或miRNA组合物的表达谱来辅助诊断被试者是否罹患慢性乙肝肝纤维化,提高了诊断的准确率。
附图说明
图1为本发明的miRNA组合物在验证集肝纤维化组的ROC曲线。
具体实施方式
下面结合附图和具体实施例对本发明作进一步说明。
实施例1慢性乙肝肝纤维化相关miRNA的筛选
病例选择:病例来自于镇江市第三人民医院2008年8月至2013年12月所有的慢性乙肝感染者进行肝穿刺病理检查的患者。病例入选标准:(1)HBsAg阳性至少6月;(2)HBVDNA>1000拷贝/毫升。排除标准如下:(1)合并其他病毒性肝炎和病毒性疾病,如HAV,HCV,HEV,HIV;(2)药物性肝损以及有规律嗜酒史;(3)标本不符合要求;(4)有使用抗乙肝病毒药物史或者肝穿刺前已开始抗病毒治疗;(5)肝穿刺前12月内有保肝药使用。共入选1210例进行过肝穿刺慢性乙肝病例,排除621例(合并其他病毒性肝炎,n=83;药物性肝损或者有规律嗜酒史,n=169;样本不符合要求,n=35;有使用抗病毒药物史,n=156;随访期间有保肝药使用,n=178)。共589例入选病例,PNALT共129例,其中HBeAg阳性48例,HBeAg阴性81例;PIALT(ALT1-2ULN,n=186),其中HBeAg阳性87例,HBeAg阴性99例;PIALT(ALT≥2ULN,n=274),其中HBeAg阳性86例,HBeAg阴性,168例。
1.样品采集
患者在首次门诊或住院时采集新鲜血液5ml于医用血清管中(无肝素抗凝),上下轻轻颠倒混匀,立即将全血置于4℃冰盒中保存,并在2h内4000g,离心10min。将上层血清转移至1.5ml离心管(RNase free)中,13000g,离心2min。最后将上清液转移至2ml旋盖尖底离心管中(RNase free),每个管子吸入250ul血清进行分装,弃去血细胞沉淀。置于-80℃长期保存。
2.总RNA提取及质检
血清RNA的抽提采用LCS TRK1001试剂盒(LC Sciences)操作说明书进行。随机抽取两个在血清中稳定表达的miRNA作为标准检测总RNA提取质量,分别为hsa-miR-16、hsa-miR-192。然后各取2μl,以上述引物对应的逆转录引物分别逆转录(反应体系为10μl);以1μl/孔的cDNA为模板,进行realtimePCR,反应体系为20μl,复孔为三个,同时做引物NTC(模板以水代替)。然后检测hsa-miR-16和hsa-miR-192PCR扩展曲线、溶解曲线以及CT值。
3.文库构建
使用Illumina Truseq Small RNA Preparation kit试剂盒参照试剂盒说明书Illumina’s TruSeq Small RNA Sample Preparation Guide构建小RNA文库,总RNA链接5'接头和3'接头后经RT-PCR扩增形成小分子RNA的cDNA文库,经过6%TBE变性胶电泳分离,将长度范围在147bp的小分子RNA切胶回收。
4.第二代测序
cDNA经纯化后在Illumina’s Cluster Station上生成DNA簇后上机(IlluminaGAIIx)进行测序。通过Illumina’s Sequencing Control Studio software version 2.8(SCS v2.8)软件实时分析测序图片并使用Illumina's Real-Time Analysis version1.8.70(RTAv1.8.70)提取base-calling。提取的原始序列利用ACGT101-miR v4.2(LCSciences)软件分析,生成RawData数据库,同时去除由于样品制备、测序化学与处理以及测序仪器的光学数码处理而产生的非纯序列。剩下的序列(长度在15和32bases)按照families进行分组,生成mappableReads。Mappable序列与最新版本的miRbase数据库以及测序物种基因组进行序列比对,鉴定该物种已知的miRNA;同时发现新的5p或者3p miRNA序列,鉴定在其它近源物种中已有报道,在该物种中崭新的miRNA序列。其中Mappable序列能与Rfam(ierRNA,tRNA,snRNA,snoRNA and others),Repbase以及mRNA序列比对上的均被去除。除此之外,为了保证筛选到高质量的基因结果,我们把reads数小于10的基因剔除掉。最后分析实验组和对照组之间差异表达的miRNAs。
通过上述测序分析,慢性乙肝轻度、中度以上肝纤维化组经过初级分析后得到8,580,434和7,485,507条原始序列,经过去除冗余后剩余659,447和441,182条可比对序列。对三数据归一化后比较,在肝纤维化不同损伤,血清miRNA在MPCHB和SPCHB两者的表达差异,共发现84条有差异显著性的miRNAs,符合表达差异倍数2倍以上,P<0.05的8个miRNA为上调基因,18个下调miRNA表达基因,见表1:
表1 慢性乙肝轻度及中度以上肝纤维化miRNA的表达差异
5、表达差异的miRNA进一步筛选:对上述表达差异的27个差异miRNA进一步筛选,筛选条件为:Ct值〈35,检测率〉75%,共筛选出5个候选miRNA,分别为:hsa-miR-190b,hsa-miR-206,hsa-miR-1285-5p,hsa-miR-10a-5p和hsa-miR-98-5p,见表2:
表2 慢性乙肝肝纤维化在训练集miRNA的差异表达
6、训练集RT-PCR进一步筛选目的miRNA:
对上阶段筛选出的5个候选miRNA使用新的训练集进行qRT-PCR检验,发现有3个差异表达miRNA存在肝纤维化组之间,hsa-miR-190b,hsa-miR-1285-5p和hsa-miR-98-5p。Logistic回归分析建立联合预测因子,经过逐步Logistic回归建立LogitP。肝纤维化组,有3个miRNA进入方程Logit P2=-4.3561+0.84629*miR_190b+0.67945*miR_1285-0.29171*miR_98,见表3:
表3 慢性乙肝轻度及中度以上肝纤维化训练集Logistic回归
验证集验证miRNA组合:
利用训练集建立的miRNA模型,对独立建立的队列验证集(轻、中度以上肝纤维化分别选择65例,132例)进行验证,评价其诊断价值。miRNA组合物在验证集肝纤维化组的ROC曲线见图1,可以看出,AUC为0.811(95%CI=0.775–0.897,灵敏度=78.7%,特异度=83.3%),说明miRNA组合物可以作为预测慢性乙肝肝纤维化的生物标志物。
序列表
<110> 镇江市第三人民医院
<120> 一种用于预测慢性乙肝肝纤维化的miRNA组合物
<140> 2018110522468
<141> 2018-09-10
<160> 9
<170> SIPOSequenceListing 1.0
<210> 1
<211> 22
<212> RNA
<213> miRNA组合物(hsa-miR-190b)
<400> 1
ugauauguuu gauauugggu uu 22
<210> 2
<211> 21
<212> RNA
<213> miRNA组合物(hsa-miR-1285-5p)
<400> 2
gaucucacuu uguugcccag g 21
<210> 3
<211> 22
<212> RNA
<213> miRNA组合物(hsa-miR-98-5p)
<400> 3
ugagguagua aguuguauug uu 22
<210> 4
<211> 21
<212> DNA
<213> miRNA组合物(hsa-miR-190b)
<400> 4
ggcggtgata tgtttgatag t 21
<210> 5
<211> 20
<212> DNA
<213> miRNA组合物(hsa-miR-190b)
<400> 5
cagtgcaggg tccgaggtat 20
<210> 6
<211> 21
<212> DNA
<213> miRNA组合物(hsa-miR-1285-5p)
<400> 6
tcgctggatc tcactttgtt g 21
<210> 7
<211> 20
<212> DNA
<213> miRNA组合物(hsa-miR-1285-5p)
<400> 7
cagtgcaggg tccgaggtat 20
<210> 8
<211> 21
<212> DNA
<213> miRNA组合物(hsa-miR-98-5p)
<400> 8
cggcgtgagg tagtaagttg t 21
<210> 9
<211> 20
<212> DNA
<213> miRNA组合物(hsa-miR-98-5p)
<400> 9
cagtgcaggg tccgaggtat 20
Claims (1)
1.一种用于早期诊断慢性乙肝肝纤维化的试剂盒,其特征在于,包括针对hsa-miR-190b的特异性引物,针对hsa-miR-1285-5p的特异性引物,针对hsa-miR-98-5p的特异性引物;所述针对hsa-miR-190b的特异性引物包括SEQ ID NO.4所示的正向引物和SEQ ID NO.5所示的反向引物,所述针对hsa-miR-1285-5p的特异性引物包括SEQ ID NO.6所示的正向引物和SEQ ID NO.7所示的反向引物,所述针对hsa-miR-98-5p的特异性引物包括SEQ IDNO.8所示的正向引物和SEQ ID NO.9所示的反向引物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811052246.8A CN109022569B (zh) | 2018-09-10 | 2018-09-10 | 一种用于预测慢性乙肝肝纤维化的miRNA组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811052246.8A CN109022569B (zh) | 2018-09-10 | 2018-09-10 | 一种用于预测慢性乙肝肝纤维化的miRNA组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109022569A CN109022569A (zh) | 2018-12-18 |
CN109022569B true CN109022569B (zh) | 2021-09-17 |
Family
ID=64621166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811052246.8A Expired - Fee Related CN109022569B (zh) | 2018-09-10 | 2018-09-10 | 一种用于预测慢性乙肝肝纤维化的miRNA组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109022569B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115029347B (zh) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒 |
CN114990159A (zh) * | 2022-05-18 | 2022-09-02 | 昆明理工大学 | 一种micorRNA206抑制HCV增殖的建立方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936629A (zh) * | 2012-11-28 | 2013-02-20 | 首都医科大学附属北京佑安医院 | 用于肝硬化及肝癌早期诊断的基于微小rna的方法和组合物 |
CN104293914A (zh) * | 2014-09-05 | 2015-01-21 | 镇江市第三人民医院 | 用于检测原发性肝细胞癌的血清miRNA标志物组合及应用 |
CN110564852A (zh) * | 2019-08-06 | 2019-12-13 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 与人类多发性骨髓瘤相关的miRNAs表达图谱模型、构建方法及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014164253A1 (en) * | 2013-03-09 | 2014-10-09 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
-
2018
- 2018-09-10 CN CN201811052246.8A patent/CN109022569B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102936629A (zh) * | 2012-11-28 | 2013-02-20 | 首都医科大学附属北京佑安医院 | 用于肝硬化及肝癌早期诊断的基于微小rna的方法和组合物 |
CN104293914A (zh) * | 2014-09-05 | 2015-01-21 | 镇江市第三人民医院 | 用于检测原发性肝细胞癌的血清miRNA标志物组合及应用 |
CN110564852A (zh) * | 2019-08-06 | 2019-12-13 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 与人类多发性骨髓瘤相关的miRNAs表达图谱模型、构建方法及应用 |
Non-Patent Citations (4)
Title |
---|
"A Serum MicroRNA Panel as Potential Biomarkers for Hepatocellular Carcinoma Related with Hepatitis B Virus";Youwen Tan等;《PLOS ONE》;20140919;第9卷(第9期);e107986 * |
"MicroRNA-190b regulates lipid metabolism and insulin sensitivity by targeting IGF-1 and ADAMTS9 in non-alcoholic fatty liver disease";Min Xu等;《JOURNAL OF CELLULAR BIOCHEMISTRY》;20180731;第119卷(第7期);第5684-5874页 * |
"血清(血浆)miRNA对慢性乙型肝炎肝纤维化非创伤性诊断价值的临床研究";张清清;《中国优秀硕士学位论文全文数据库医药卫生科技辑》;20170315(第03期);E064-112 * |
"血清miRNA非创伤性诊断青海地区慢性乙型肝炎肝纤维化患者的临床研究";李萍英等;《第九届全国疑难及重症肝病大会论文集》;20170602;第1页 * |
Also Published As
Publication number | Publication date |
---|---|
CN109022569A (zh) | 2018-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010043114A1 (zh) | 血清/血浆miRNA在HBV感染和肝癌早期诊断中的应用 | |
JP2017018088A (ja) | 川崎病の検出方法及びそのためのキット | |
CN107338324B (zh) | 用于诊断不明原因复发性流产的血清lncRNA标志物、引物组及应用和试剂盒 | |
CN108977533B (zh) | 一种用于预测慢性乙肝炎症损伤的miRNA组合物 | |
CN104293914A (zh) | 用于检测原发性肝细胞癌的血清miRNA标志物组合及应用 | |
CN111826466B (zh) | 乙型肝炎感染患者或携带者外泌体miRNA分子标志物组合及筛查试剂盒 | |
CN102286464B (zh) | 尿毒症长链非编码核糖核酸差异性表达图谱模型及其构建方法 | |
CN109022569B (zh) | 一种用于预测慢性乙肝肝纤维化的miRNA组合物 | |
CN113755597B (zh) | 外周血外泌体miRNA联合标志物在制备检测HBV阳性肝硬化早期肝癌试剂盒中的应用 | |
CN108220416B (zh) | 一种用于检测阴虚上火体质血清特异性miRNA的试剂盒及其应用 | |
CN108148908B (zh) | 动脉粥样硬化性肾动脉狭窄诊断分子标记物的应用 | |
CN105671179B (zh) | 血清microRNA在肝癌诊断中的应用及诊断试剂盒 | |
CN113980968B (zh) | 一种新的ra标志长链非编码rna及其应用 | |
CN102021169A (zh) | 一种血清/血浆miRNA组合物及其应用 | |
CN111455037B (zh) | 基于血浆外泌体环状rna的冠心病分子诊断标志物及其应用 | |
CN108424960B (zh) | 一种LncRNA作为深静脉血栓形成诊断标志物的应用 | |
CN110527721B (zh) | 一种陈旧性结核病标志物及其应用 | |
CN103014165A (zh) | 可用于检测与冠心病相关的pla2g7基因启动子区甲基化程度的试剂盒及其应用 | |
CN113355408A (zh) | 一种用于检测/疗效评价早发型精神分裂症的分子标志物及其应用 | |
CN113025707A (zh) | 生物标志物在制备诊断湿热困脾型2型糖尿病的产品中的应用、试剂盒 | |
CN112522391A (zh) | hsa_circ_0008961作为痛风诊断标志物的应用 | |
CN112266955A (zh) | 一种强直性脊柱炎诊断标志物及应用 | |
CN110699450A (zh) | miRNA生物标志物在肝脏疾病诊断和预后判断中的应用 | |
CN110172508A (zh) | 一种abca13用于诊断肝衰竭的新用途及试剂盒及试剂盒用于诊断肝衰竭的应用 | |
CN109371129A (zh) | hsa_circRNA_0000798作为肝癌早期诊断或预后评估生物标记物的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20210917 |